Posted by Michael Wonder on 28 Feb 2017
FDA approves once-daily Qtern (dapagliflozin and saxagliptin) tablets for adults with type 2 diabetes mellitus
28 February 2017 - Qtern fixed-dose combination will provide an additional oral medicine option for patients taking Farxiga (dapagliflozin) to improve blood sugar level.
AstraZeneca today announced that the US FDA has approved once-daily Qtern (10 mg dapagliflozin and 5 mg saxagliptin) for the treatment of type 2 diabetes. The new medicine is indicated as an adjunct to diet and exercise to improve glycaemic (blood sugar level) control in adults with type 2 diabetes who have inadequate control with dapagliflozin (10 mg) or who are already treated with dapagliflozin and saxagliptin.
